Waldencast plc Warrant (WALDW)

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

Waldencast reported mixed performance in H1 2025, with Obagi Medical and Milk Makeup experiencing growth challenges. The company acquired Novaestiq Corp., expanded into aesthetics, and initiated a strategic review to maximize shareholder value while adjusting full-year revenue and EBITDA guidance.

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Waldencast has acquired Novaestiq Corp. and the U.S. rights to the Saypha® injectable hyaluronic acid gel line, expanding Obagi Medical's portfolio into dermal fillers and positioning the company at the intersection of skincare and aesthetic treatments.